Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse MKT  >  Ibio Inc    IBIO

IBIO INC (IBIO)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsCompany 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE

IBIO, INC. : Other Events (form 8-K)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/12/2018 | 11:32pm CEST
Item 8.01 Other Events



On July 12, 2018, iBio, Inc. (the "Company") issued 1,500,000 shares of common stock to A.G.P./Alliance Global Partners (the "Underwriter") in connection with the Underwriter partially exercising its over-allotment option at the public offering price of $0.90 per share. After giving effect to the partial exercise of the over-allotment option, the total number of shares of common stock sold by the Company in the public offering increased to 5,850,000 shares and gross proceeds increased to approximately $17,350,000. The Company intends to use the over-allotment proceeds for working capital and general corporate purposes.

© Edgar Online, source Glimpses

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on IBIO INC
09/18IBIO : Management's Discussion and Analysis of Financial Condition and Results o..
AQ
08/22IBIO, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule ..
AQ
08/22iBio, Inc. Announces NYSE American Acceptance of Plan of Compliance
GL
07/12IBIO, INC. : Other Events (form 8-K)
AQ
07/09iBio Establishes Strategic Commercial Relationship with CC-Pharming Ltd. of B..
GL
06/27Free Technical Research on Nektar Therapeutics and Three More Biotech Equitie..
AC
06/27IBIO, INC. : Entry into a Material Definitive Agreement, Amendments to Articles ..
AQ
06/27iBio, Inc. Closes $16,000,000 Public Offering
GL
06/23IBIO : Prices $16,000,000 Public Offering
AQ
06/22IBIO : Out with $16M Public Offering
AQ
More news
News from SeekingAlpha
07/15WEEK IN REVIEW : Tasly Biopharma Completes Pre-IPO Round At $1.9 Billion Valuati.. 
Chart IBIO INC
Duration : Period :
Ibio Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Managers
NameTitle
Robert B. Kay Executive Chairman & Chief Executive Officer
Robert L. Erwin President
James P. Mullaney Chief Financial Officer
Terence E. Ryan Chief Scientific Officer
Glenn J. Chang Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
IBIO INC-49.18%0
JOHNSON & JOHNSON0.59%376 820
PFIZER20.13%253 595
NOVARTIS-0.80%216 184
ROCHE HOLDING LTD.-4.06%211 637
MERCK AND COMPANY24.36%186 114